RT Book, Section
A1 Lin, Jules
A1 Chang, Andrew C.
A2 Sugarbaker, David J.
A2 Bueno, Raphael
A2 Colson, Yolonda L.
A2 Jaklitsch, Michael T.
A2 Krasna, Mark J.
A2 Mentzer, Steven J.
A2 Williams, Marcia
A2 Adams, Ann
SR Print(0)
ID 1105848078
T1 Genomics, Molecular Markers, and Targeted Therapies in Esophageal Cancer
T2 Adult Chest Surgery, 2e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-178189-3
LK accesssurgery.mhmedical.com/content.aspx?aid=1105848078
RD 2024/04/24
AB Esophageal  carcinomas  remain  a  leading  cause  of  cancer-related  death  worldwide,  and  the  prognosis  remains  poor  with  5-year  overall  survival  of  only  17%.1  In  the  mid-1990s,  esophageal  adenocarcinoma  (EAC)  overtook  squamous  cell  carcinoma  (ESCC)  as  the  most  common  esophageal  cancer  in  the  United  States.2,3  Risk  factors  include  smoking,  obesity,  and  Barrett  metaplasia  secondary  to  gastroesophageal  reflux,  whereas  infection  with  Helicobacter  pylori  appears  to  be  protective.4